arrow_back Trending Legislation
Share share

Ensuring State Access to COVID-19 Therapies and Supplies

This bill aims to ensure that state governments have equal access to critical therapies, such as monoclonal antibodies, and supplies needed to combat the COVID-19 pandemic. It means the federal government cannot limit states' access to these resources or prioritize its own contracts over state contracts for supplies. Additionally, states will be able to use relief funds to purchase essential items they previously couldn't acquire due to federal prioritization.
Key points
Federal government cannot limit state access to key therapies like monoclonal antibodies.
State contracts for COVID-19 supplies cannot be deprioritized over federal contracts.
States can use existing relief funds to purchase supplies previously unavailable due to federal prioritization.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
To amend the Federal Food, Drug, and Cosmetic Act and the Defense Production Act of 1950 to prohibit the Federal Government from limiting State access to key therapies, such as monoclonal antibodies, and from prioritizing Federal contracts over State contracts relating to purchasing supplies to combat the COVID-19 pandemic.
Print number: HR 6832
Sponsor: Rep. Cloud, Michael [R-TX-27]
Process start date: 2022-02-25
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Ensuring State Access to COVID-19 Therapies and Supplies

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HR 6832.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2022-02-25.

What are the main provisions?

Key points include:

  • Federal government cannot limit state access to key therapies like monoclonal antibodies.
  • State contracts for COVID-19 supplies cannot be deprioritized over federal contracts.
  • States can use existing relief funds to purchase supplies previously unavailable due to federal prioritization.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Cloud, Michael [R-TX-27].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

Analysis and Potential Impact of HR 6832

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health